179 related articles for article (PubMed ID: 37099132)
1. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection.
Wang S; Qi C; Ding J; Li D; Zhang M; Ji C; Jiang F; Teng F; Yu J; Qian X; Wang F; Shen L; Gao J; Yang Z; Zhang C; Zhu H
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2802-2817. PubMed ID: 37099132
[TBL] [Abstract][Full Text] [Related]
2.
Qi C; Guo R; Chen Y; Li C; Liu C; Zhang M; Zhang C; Zhang X; Hou X; Chen B; Jia B; Yang Z; Shen L; Zhu H
J Nucl Med; 2024 Jun; 65(6):856-863. PubMed ID: 38604764
[No Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery.
Zhao C; Rong Z; Ding J; Wang L; Wang B; Ding L; Meng L; Meng X; Wang F; Yang Z; Shou C; Zhu H
Mol Pharm; 2022 Oct; 19(10):3530-3541. PubMed ID: 35344359
[TBL] [Abstract][Full Text] [Related]
5. Development and comparison of three
Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
Wang S; Zhu H; Ding J; Wang F; Meng X; Ding L; Zhang Y; Li N; Yao S; Sheng X; Yang Z
Clin Nucl Med; 2021 May; 46(5):382-388. PubMed ID: 33512952
[TBL] [Abstract][Full Text] [Related]
7. Exploration of radionuclide labeling of a novel scFv-Fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment.
Li D; Ding L; Chen Y; Wang Z; Zeng Z; Ma X; Huang H; Li H; Qian X; Yang Z; Zhu H
Eur J Med Chem; 2024 Feb; 266():116134. PubMed ID: 38266552
[TBL] [Abstract][Full Text] [Related]
8. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
9. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer.
Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C
Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487
[TBL] [Abstract][Full Text] [Related]
10. [
Zeng Z; Li L; Tao J; Liu J; Li H; Qian X; Yang Z; Zhu H
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1221-1232. PubMed ID: 38062170
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
12. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and first-in-human evaluation of
Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
[TBL] [Abstract][Full Text] [Related]
14. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
15. Comparison of
Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
[TBL] [Abstract][Full Text] [Related]
16. [
Nakajo M; Jinguji M; Tani A; Kajiya Y; Nandate T; Kitazano I; Yoshiura T
Mol Imaging Biol; 2020 Dec; 22(6):1609-1620. PubMed ID: 32651718
[TBL] [Abstract][Full Text] [Related]
17. Impact of
Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the diagnostic efficacy of
Zhang Z; Jia G; Pan G; Cao K; Yang Q; Meng H; Yang J; Zhang L; Wang T; Cheng C; Zuo C
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2877-2888. PubMed ID: 35243518
[TBL] [Abstract][Full Text] [Related]
19. Multiple metabolic parameters and visual assessment of
Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
[TBL] [Abstract][Full Text] [Related]
20. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
